Invitrogen Stumbles in Q3 as BioReliance Woes Continue; Firm Predicts Q4 Recovery | GenomeWeb

Disappointing results from its BioProduction unit, among other factors, pushed Invitrogen's net earnings lower and produced total organic revenue growth of only 1 percent for the third quarter, the firm announced last week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.